Cargando...
Correlating EGFR Expression with Receptor-Binding Properties and Internalization of (64)Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines
The anti–epidermal growth factor receptor (anti-EGFR) antibody cetuximab is clinically approved for the treatment of EGFR-expressing metastatic colorectal cancer and advanced head and neck cancer. Overexpression of EGFR has also been found in more than 70% of carcinomas of the cervix. The overall go...
Gardado en:
| Publicado en: | J Nucl Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2008
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4277815/ https://ncbi.nlm.nih.gov/pubmed/18703609 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.108.052316 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|